138 related articles for article (PubMed ID: 21431636)
1. Cytogenetics of myeloproliferative neoplasms.
Campbell LJ
Methods Mol Biol; 2011; 730():89-98. PubMed ID: 21431636
[TBL] [Abstract][Full Text] [Related]
2. Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Dunlap J; Kelemen K; Leeborg N; Braziel R; Olson S; Press R; Huang J; Gatter K; Loriaux M; Fan G
Am J Clin Pathol; 2011 May; 135(5):709-19. PubMed ID: 21502425
[TBL] [Abstract][Full Text] [Related]
3. Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3.
Tzankov A; Sotlar K; Muhlematter D; Theocharides A; Went P; Jotterand M; Horny HP; Dirnhofer S
J Clin Pathol; 2008 Aug; 61(8):958-61. PubMed ID: 18663058
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2007 Sep; 255(1):12-25. PubMed ID: 17383090
[TBL] [Abstract][Full Text] [Related]
5. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.
Bacher U; Haferlach T; Kern W; Hiddemann W; Schnittger S; Schoch C
Ann Hematol; 2005 Apr; 84(4):250-7. PubMed ID: 15692838
[TBL] [Abstract][Full Text] [Related]
6. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
Tefferi A; Thiele J; Vardiman JW
Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic analysis in acute myeloid leukaemia.
Campbell LJ; White JS
Methods Mol Biol; 2011; 730():63-77. PubMed ID: 21431634
[TBL] [Abstract][Full Text] [Related]
8. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes.
Haferlach C; Rieder H; Lillington DM; Dastugue N; Hagemeijer A; Harbott J; Stilgenbauer S; Knuutila S; Johansson B; Fonatsch C
Genes Chromosomes Cancer; 2007 May; 46(5):494-9. PubMed ID: 17311250
[TBL] [Abstract][Full Text] [Related]
9. Concurrence of B-lymphoblastic leukemia and myeloproliferative neoplasm with copy neutral loss of heterozygosity at chromosome 1p harboring a MPL W515S mutation.
Tao J; Zhang X; Lancet J; Bennett JM; Cai L; Papenhausen P; Moscinski L; Zhang L
Cancer Genet; 2014; 207(10-12):489-94. PubMed ID: 25453399
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
Tefferi A; Levine RL; Kantarjian H
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):114-9. PubMed ID: 19147089
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathology of myeloproliferative neoplasms.
Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
[TBL] [Abstract][Full Text] [Related]
12. Genomic analysis of clonal eosinophils by CGH arrays reveals new genetic regions involved in chronic eosinophilia.
Arefi M; Robledo C; Peñarrubia MJ; García de Coca A; Cordero M; Hernández-Rivas JM; García JL
Eur J Haematol; 2014 Nov; 93(5):422-8. PubMed ID: 24813417
[TBL] [Abstract][Full Text] [Related]
13. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN).
Kodali S; Chen C; Rathnasabapathy C; Wang JC
Leuk Res; 2009 Dec; 33(12):e236-9. PubMed ID: 19625083
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukemia: cytogenetic methods and applications for diagnosis and treatment.
Morris CM
Methods Mol Biol; 2011; 730():33-61. PubMed ID: 21431633
[TBL] [Abstract][Full Text] [Related]
15. The myeloid disorders: background.
Swansbury J
Methods Mol Biol; 2003; 220():23-42. PubMed ID: 12744204
[TBL] [Abstract][Full Text] [Related]
16. Application of growth factor stimulants improves cytogenetic analysis of chronic myeloproliferative disorder patients without alteration to cell lineage or clonality.
Vaughan BR; Scott MA; Howard JD; Nacheva EP
Cancer Genet Cytogenet; 2007 Jun; 175(2):98-106. PubMed ID: 17556065
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic interface between histology and molecular tests in myeloproliferative disorders.
Tefferi A; Vardiman JW
Curr Opin Hematol; 2007 Mar; 14(2):115-22. PubMed ID: 17255788
[TBL] [Abstract][Full Text] [Related]
18. Myeloproliferative disorders.
Bench AJ; Cross NC; Huntly BJ; Nacheva EP; Green AR
Best Pract Res Clin Haematol; 2001 Sep; 14(3):531-51. PubMed ID: 11640868
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetics in the management of Philadelphia-negative myeloproliferative neoplasms: an update by the Groupe francophone de cytogénétique hématologique (GFCH).
Bilhou-Nabéra C; Bidet A; Eclache V; Lippert E; Mozziconacci MJ
Ann Biol Clin (Paris); 2016 Oct; 74(5):517-523. PubMed ID: 27477946
[TBL] [Abstract][Full Text] [Related]
20. Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders.
Bacher U; Haferlach T; Schoch C
Cancer Genet Cytogenet; 2005 Jul; 160(2):179-83. PubMed ID: 15993276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
